Potassium Phosphates in Sodium Chloride
Brand Names: Potassium Phosphates in Sodium Chloride Generic
Methodology & AI Transparency ⓘ
Potassium Phosphates in Sodium Chloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Potassium Phosphates in Sodium Chloride (4.48 mg/mL / 4.72 mg/mL Injection; NDC 70121-1722) as a intravenous-route osmotic laxative formulation manufactured/labeled by Amneal Pharmaceuticals LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
- 2 Real-world patient consensus: 94% patient "Worth It" rating across 11 anonymous logs for Potassium Phosphates in Sodium Chloride (RxNorm RXN-701211722-2584).
- 3 Typical cash cost range: Dispensing cost comparison spans $40.09 mail/discount cash up to $98.22 uninsured retail (federal NADAC $0.7800).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Potassium Phosphates in Sodium Chloride): application-site erythema (6.3%), mild local dryness (5.7%), transient stinging (4%).
Ask our AI Specialists anything about Potassium Phosphates in Sodium Chloride
Potassium Phosphates in Sodium Chloride Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Potassium Phosphates in Sodium Chloride (4.48 mg/mL / 4.72 mg/mL Injection; NDC 70121-1722) as a intravenous-route osmotic laxative formulation manufactured/labeled by Amneal Pharmaceuticals LLC when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Potassium Phosphates in Sodium Chloride exerts selective osmotic laxative pharmacodynamic activity across 4.48 mg/mL / 4.72 mg/mL Injection (intravenous-route route, manufactured/labeled by Amneal Pharmaceuticals LLC), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 70121-1722).
Systemic exposure to Potassium Phosphates in Sodium Chloride reflects Complete (~100%) parenteral systemic delivery for Potassium Phosphates in Sodium Chloride (4.48 mg/mL / 4.72 mg/mL Injection) absorption kinetics and local esterase/enzymatic cleavage of potassium phosphates in sodium chloride with minimal hepatic cytochrome burden, sustaining receptor engagement across a Depot mucosal/cutaneous persistence without significant systemic accumulation of Potassium Phosphates in Sodium Chloride half-life window (rapid intravascular/parenteral onset within 15–45 minutes after potassium phosphates in sodium chloride administration response profile).
Dosing protocols (4.48 mg/mL / 4.72 mg/mL Injection or 4.48 mg/mL or 4.72 mg/mL) balance efficacy (94.00% patient satisfaction across 11 logs) against application-site erythema (6.3% of reports), mild local dryness (5.7% of reports), transient stinging (4% of reports), with strict avoidance in prior anaphylaxis, angioedema, or severe hypersensitivity to potassium phosphates in sodium chloride or potassium phosphates in sodium chloride excipients; co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 potassium phosphates in sodium chloride spl.
Combining Potassium Phosphates in Sodium Chloride with ACE inhibitors, ARBs, or aldosterone blockers can shift serum potassium and eGFR.
Avoid overlapping osmotic laxative prescriptions alongside Potassium Phosphates in Sodium Chloride to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Prior anaphylaxis, angioedema, or severe hypersensitivity to Potassium Phosphates in Sodium Chloride or Potassium Phosphates in Sodium Chloride excipients
- Co-administration with prohibited interacting drugs or decompensated organ failure per 2026-07-01 Potassium Phosphates in Sodium Chloride SPL
Logged Side-Effect Incidence (11 Reports)
Potassium Phosphates in Sodium Chloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Potassium Phosphates in Sodium Chloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Improvements in irritability with sertraline versus placebo: Findings from the: What a 292-Participant Study Found There was a significant treatment arm-by-time interaction (F = 6.96, df = 6, 1418, p <0.0001) suggesting that changes in irritability with sertraline differed from placebo. Journal of affective disorders • 2020-10-01 • Randomized Controlled Trial | N = 292 | 93/100 | PMID 32658822 ↗ |
| New Insights on Modified-release nicotinamide for the treatment of hyperphosphataemia in: What a 358-Participant Study Found NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association • 2023-03-31 • Phase III Randomized Trial | N = 358 | 93/100 | PMID 35751625 ↗ |
| New Insights on Magnesium and potassium supplementation on trouble sleeping and sleep hormones in: What a 320-Participant Study Found The study revealed that magnesium, potassium, and magnesium and potassium combined had a significant effect on serum cortisol and melatonin levels (sleep hormones). Frontiers in endocrinology • 2024-01-15 • Randomized Controlled Trial | N = 320 | 93/100 | PMID 39534260 ↗ |
| New Insights on Fixed-dose Combinations of Amlodipine/Losartan Potassium/Chlorthalidone and: What a 328-Participant Study Found Of 330 patients from 33 medical centers, 328 patients who had available efficacy data were analyzed. Clinical therapeutics • 2017-10-15 • Phase III Randomized Trial | N = 328 | 93/100 | PMID 28939406 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of a Novel Stannous Fluoride Toothpaste Stabilized With Nitrate and The results indicate that the SNaP toothpaste provides a greater level of efficacy in the removal of extrinsic tooth stain as compared to a regular fluoride toothpaste when used twice a day, as measured with Lobene stain. Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995) • 2024-01-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39566487 ↗ |
Potassium Phosphates in Sodium Chloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7800/unit (~$23.40/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $98.22 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 11 Anonymous DotMD Community Micro-Logs | $40.09 / mo | View logs ↓ |
Potassium Phosphates in Sodium Chloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Potassium Phosphates in Sodium Chloride RxNorm Concept ID | RXN-701211722-2584 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7800 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $98.22 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $40.09 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 94.00% Worth It (11 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Potassium Phosphates in Sodium Chloride Patient Community, Cohort Filters & Dosage Logs
Deterministic Potassium Phosphates in Sodium Chloride reference combining NIH RxNorm (RXN-701211722-2584), Medicaid NADAC ($0.7800/unit), and anonymous cohort outcomes (94% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Potassium Phosphates in Sodium Chloride community threads and patient logs by age, biological sex, dosage, and treatment duration.